

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

NCT06682117

| | |
|------------|------------------|
| Status | RECRUITING |
| Phase | Not Applicable |
| Sponsor | Fudan University |
| Enrollment | 9 participants |

Key Eligibility Criteria

Inclusion (19)

- years.
 - Histologically or cytologically confirmed advanced solid tumor, with at least one tumor lesion measurable (basis RECIST1.1 standard).
 - HLA typing was HLA-A0201/1101/2402 (containing at least one of the typing, according to the central laboratory issued).
 - Paraffin-embedded tumor tissue sections or biopsy tumor tissues within 3 years (for tumors with easy sampling).
 - Before enrollment, systemic standard treatment failure or standard treatment intolerance, and meet the following tumor requirements : new antigen positive head and neck tumors, non-small cell lung cancer without driver genes (no EGFR sensitive mutation / ALK fusion positive), esophageal squamous cell carcinoma).
- ... and 14 more (see full listing online)

Exclusion (6)

- Pregnant or lactating women.
 - Patients with a history of severe immediate allergies to the cells and any drugs used in this study.
 - Those with a history of organ transplantation.
 - Known central nervous system metastasis.
 - Any active autoimmune disease or any autoimmune disease that has been determined by the researchers to be unsuitable for this study.
- ... and 1 more (see full listing online)

Locations (1 total)

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China